Budoprutug
Immune-Mediated Diseases (Undisclosed)
ClinicalActive
Key Facts
About Climb Bio
Climb Bio is a clinical-stage biotech developing monoclonal antibodies targeting B cells for immune-mediated diseases. Its pipeline includes budoprutug (anti-CD19) and CLYM116 (anti-APRIL), both in clinical development for indications with high unmet need. The company employs a de-risked strategy by focusing on validated targets and proven modalities, led by an experienced team with a corporate headquarters in Wellesley Hills, Massachusetts. As a private, pre-revenue company, it is actively engaging with investors to advance its clinical programs.
View full company profile